Anthrarobin

Anthrarobin

SCHEMBL187228

Oc1ccc2c(O)c3ccccc3cc2c1O

nearest known ligand 0.68

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN22 Q9Y2R2 1/20 0.68
TRPM4 Q8TD43 1/20 0.50
NQO2 P16083 1/20 0.48
HDAC3 O15379 2/20 0.47
HDAC4 P56524 2/20 0.47
HDAC1 Q13547 2/20 0.47
HDAC2 Q92769 2/20 0.47
HDAC10 Q969S8 2/20 0.47
HDAC6 Q9UBN7 2/20 0.47
HDAC5 Q9UQL6 2/20 0.47
HDAC7 Q8WUI4 1/20 0.47
HDAC11 Q96DB2 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
HDAC9 Q9UKV0 1/20 0.47
ALOX5 P09917 1/20 0.46
ALDH1A1 P00352 1/20 0.44
HIF1A Q16665 1/20 0.44
CYP1B1 Q16678 1/20 0.44
HSD17B10 Q99714 1/20 0.44
IDO1 P14902 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Anthrarobin SCHEMBL29404728 1.00 PTPN22 (0.68) PTPN22TRPM4NQO2HDAC3HDAC4
Anthrarobin SCHEMBL29523367 1.00 PTPN22 (0.68) PTPN22TRPM4NQO2HDAC3HDAC4
SCHEMBL25428008 0.83 ALDH1A1 (0.62) PTPN22TRPM4HDAC3HDAC4HDAC1
SCHEMBL30196661 0.83 CYP1A2 (0.60) PTPN22TRPM4NQO2HDAC3HDAC4
SCHEMBL2002444 0.83 CYP1A2 (0.60) PTPN22TRPM4NQO2HDAC3HDAC4
SCHEMBL13763201 0.82 PTPN22 (0.55) PTPN22TRPM4NQO2ALOX5ALDH1A1
SCHEMBL30822054 0.82 PTPN22 (0.55) PTPN22TRPM4NQO2ALOX5ALDH1A1
Hydrochloric Acid SCHEMBL28347175 0.81 PTPN22 (1.00) PTPN22ALDH1A1HSD17B10IDO1CYP1A2
SCHEMBL29613822 0.81 PTPN22 (1.00) PTPN22ALDH1A1HSD17B10IDO1CYP1A2
SCHEMBL28483 0.81 PTPN22 (1.00) PTPN22ALDH1A1HSD17B10IDO1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1001 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240315965-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2024-09-26 US claimed
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2023-03-23 US claimed
WO-2022182527-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2022-09-01 WO claimed
WO-2022182523-A1 COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2022-09-01 WO claimed
WO-2021158573-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO claimed
WO-2021158575-A1 COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO claimed
WO-2021042001-A1 COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES Natural Extraction Systems, LLC (US) 2021-03-04 WO claimed
CN-110337590-A The identification and treatment of tumour characterized by neonatal Fc receptor is overexpressed 奥胡斯大学 2019-10-15 CN claimed
CN-109900774-A MALDI-TOF-MS is improved to the method for polystyrene micro-/ nano particle detections sensitivity by high-temperature process 中国科学院生态环境研究中心 2019-06-18 CN claimed
CN-109789146-A chemokine receptor modulators and uses thereof FLX生物公司 2019-05-21 CN claimed
US-6153226-A VIRICIDAL COMPOSITION COMPRISING A SYNERGISTIC MIXTURE OF A PHENOL COMPONENT AND PROPOLIS; THE PHENOL IS A MONO- OR POLYHYDROXYLATED COMPOUND COMPRISING A NONFUSED OR FUSED BENZENE RING FILECO (FR) 2000-11-28 US claimed
CN-1260355-A Anti-reflection coating polymer and preparing method thereof HYUNDAI ELECTRONICS IND (KR) 2000-07-19 CN claimed
CN-1047472-C Solid state electrochemical cell containing a proton-donating aromatic compound ELECTRO CHEM RES (IL) 1999-12-15 CN claimed
EP-0525073-B1 ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA DU PONT (US) 1994-05-25 EP claimed
EP-0525073-A1 ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA. DU PONT (US) 1993-02-03 EP claimed
CN-1056813-A The therapeutic combination that contains a kind of phenolic compounds and propolis is as against lipid capsid viruses, particularly anti-herpesvirus FILECO SA (FR) 1991-12-11 CN claimed
WO-1991015954-A1 ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA E.I. DU PONT DE NEMOURS AND COMPANY (US) 1991-10-31 WO claimed
US-4954345-A CORTICOSTEROIDS AND-OR TRIHYDROXYANTHRACENES ROHM PHARMA GMBH (DE) 1990-09-04 US claimed
EP-0046270-A1 Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them INTERx RESEARCH CORPORATION (US) 1982-02-24 EP claimed
US-4269952-A Preparation of glycidyl polyarylethers RHONE-POULENC INDUSTRIES (FR) 1981-05-26 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES FABP2, FABP4, GUSB PTPN22 4628/4885TRPM4 1231/4885NQO2 1907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.